GSK to present 43 Abstracts at ATS 2025, highlighting advances in asthma, COPD and respiratory innovation

GSK plc announced data from across its respiratory portfolio will be presented in 43 abstracts, including four late-breaking submissions, at the 2025 American Thoracic Society (ATS) International Congress in San Francisco (16 – 21 May). Key presentations aim to strengthen our understanding of optimal patient care to advance the prevention and treatment of diseases like asthma and chronic obstructive pulmonary disease (COPD).

Additional analyses from the MATINEE phase III trial

The MATINEE trial, recently published in The New England Journal of Medicine, assessed the efficacy and safety of mepolizumab in a wide spectrum of patients with COPD and type 2 inflammation, characterised by blood eosinophil count, including the most severe and difficult to treat as categorised in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.¹

New sub-analyses expand body of evidence from MATINEE by evaluating the rate of COPD exacerbations, including those that lead to emergency department visits and/or hospitalisation. Key patient subgroups of interest were assessed including those with cardiovascular comorbidities, varying severities of airflow obstruction, and with chronic bronchitis, emphysema-only or both. GSK will also present an analysis of the relationship between risk of severe exacerbation and healthcare burden in patients with COPD.

Sub-analyses from the SWIFT-1 and SWIFT-2 phase III trials

Updates from SWIFT-1 and SWIFT-2, the trials assessing the efficacy and safety of twice-yearly dosing of depemokimab in asthma with type 2 inflammation, characterised by blood eosinophil count, include a post hoc analysis of exacerbations and quality of life in patients with uncontrolled symptoms. Data from a new pooled assessment highlight improvements in overall health and risk of exacerbations resulting from sustained suppression of type 2 inflammation. Further analyses from the SWIFT programme explored geographical variation in asthma exacerbation rate, including in China, where patients did not have access to respiratory biologics at the time of the trial.

GSK will also present in a late-breaking session a first of its kind, real-world study evaluating the relationship between biologic adherence and clinical outcomes, specifically exacerbations and oral corticosteroid use.

Additional analyses demonstrate GSK ambition to lead advances in complex respiratory challenges

• Analyses supporting development of camlipixant to treat the continued burden of refractory chronic cough (RCC), including a model-based dose–response meta‑analysis evaluating reduction in taste disturbance side effects, seen across the P2X3 class, with camlipixant.
• A real-world European cohort study evaluating the ambition of clinical remission in patients with severe asthma treated with mepolizumab.
• New data showing the externally verified carbon footprints of salbutamol (also known as albuterol in the US) in the current metered dose inhaler (MDI) with propellant HFA-134a, a potential future MDI with next-generation candidate propellant HFA-152a, and a dry powder inhaler (DPI).

View a full list of GSK’s key presentations at ATS 2025 HERE